New Phase 3 Data Announced on Efficacy of Tapinarof for Adults, Children with Atopic Dermatitis

These new, positive data from the ADORING Phase 3 development program showed no new safety signals with long-term use as well as a significant reduction in disease burden.

Related Keywords

Oregon ,United States ,Philip Brown ,Eric Simpson ,Eczema Center ,Dermavant Sciences ,Drug Administration ,Oregon Health Science University ,Eczema Area ,Severity Index ,Oregon Health ,Science University ,Validated Investigator Global Assessment ,Atopic Dermatitis ,Maximal Usage Pharmacokinetics ,Chief Medical Officer ,Eczema ,Sad ,Tapinarof ,Vtama ,Dermavant ,